Author argues IMRN is a bottomed low-float biotech with military backing, upcoming product launch, and no dilution risk.
IMRN — LONG The author argues IMRN is a bottomed low-float biotech with huge backing from the military and Department of Defense, and ongoing research relationships with major US military institutions. Catalysts include the imminent launch of ProIBS (originally scheduled for Q4) and initiation of a Phase 2 trial for IMM-200 in the first half of 2026. The author notes no dilution with cash for the next year and a large gap to fill on the daily chart toward the 52-week high of $2.50 from the current $1.00.
IMRN is a pharmacuetical play with huge backing by the military and department of defense. They have ongoing research relationships with major US military institutions They are planning to launch ProIBS any day now (originally scheduled for Q4) + are initiating a phase 2 clinical trial for IMM-200 during the first half of 2026..
This Reddit post, published January 12, 2026, features u/blakeley314 discussing IMRN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/blakeley314 · Tickers: IMRN